Scancell shares healthy following patent approval award in Japan

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.

The same patent has already been approved in the US, Europe and Australia.

Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market.

"Scancell will continue building its growing portfolio of intellectual property in parralel with driving the clinical trial programme on SCIBI forward during 2013."

SCIBI is Scancell's first cancer vaccine which is currently being developed for the treatment of melanoma.

Scancell's share price was up 6.37% to 41.75p at 11:01 on Wednesday.

MF

Recommended

Aviva: a share for income investors to tuck away
Share tips

Aviva: a share for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
18 May 2022
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Three fast-growing, undervalued UK mid-cap stocks to buy now
Share tips

Three fast-growing, undervalued UK mid-cap stocks to buy now

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing UK mid-cap stocks to buy now.
18 May 2022
Should you buy Vodafone shares, or steer clear?
Share tips

Should you buy Vodafone shares, or steer clear?

Vodafone grew revenue by 4% and profit by 11% last year, and offers investors a 6.4% dividend yield. So should you buy Vodafone shares? Rupert Hargrea…
17 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022
Value is starting to emerge in the markets
Investment strategy

Value is starting to emerge in the markets

If you are looking for long-term value in the markets, some is beginning to emerge, says Merryn Somerset Webb. Indeed, you may soon be able to buy tra…
16 May 2022